Physician profile
David P Manion
NPI 1447297502
$6,044.10
in general payments reported to CMS, 2019-2025
28 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $325 · 2021: $674 · 2022: $943 · 2023: $918 · 2024: $1,223 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,746 · Education: $61.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,746.24 |
| Education | $61.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,326.91 | 2019-2025 | |
| Janssen Biotech, INC. | $802.44 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $586.14 | 2019-2025 | Ilumya |
| Genzyme Corporation | $348.27 | 2020-2025 | |
| Galderma Laboratories, L.P. | $262.46 | 2020-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $257.41 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $243.19 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $236.72 | 2020-2024 | |
| Pfizer INC. | $156.97 | 2019-2025 | |
| Lilly USA, LLC | $116.54 | 2020-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $77.76 | 2023-2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $77.61 | 2021-2025 | Nuzyra |
| Almirall LLC | $71.95 | 2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $56.01 | 2021-2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $52.84 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $47.18 | 2022-2023 | Seglentis |
| Incyte Corporation | $44.94 | 2024-2025 | Opzelura |
| Strata Skin Sciences, INC. | $42.17 | 2024 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.53 | 2019-2021 | |
| Epi Health, LLC | $31.19 | 2022 | |
| Ucb, INC. | $30.75 | 2025 | Bimzelx |
| Dermira, INC. | $28.69 | 2019-2021 | |
| Botanix Sb INC | $24.06 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $22.63 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.89 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.70 | 2023 | Spevigo |
| Amgen INC. | $15.10 | 2024 | Otezla |
| Merck Sharp & Dohme LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Manion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.